New Stock Debut | Nazzhen Technology (09856) Lists on First Day, Opens 11.04% Higher in Early Trading; Company Ranks Fifth Among All Professional Optical Module Manufacturers Globally
Nazzhen Technology (09856) debuted on its first day of listing. According to the announcement, the offer price was HK$32.96 per share, with a total of 172 million shares issued, each board lot comprising 100 shares, and net proceeds of approximately HK$5.445 billion. As of press time, the stock rose 11.04% to HK$36.6, with turnover of HK$654 million.
Nazzhen Technology (09856) debuted on its first day of listing. According to the announcement, the offer price was HK$32.96 per share, with a total of 172 million shares issued, one board lot of 100 shares, and net proceeds of approximately HK$5.445 billion. As of press time, the stock rose 11.04% to HK$36.6, with a turnover of HK$654 million.
Public information shows that Nazzhen Technology is an established supplier of optical communications and optical connectivity products, dedicated to the research and development, manufacturing, and sales of optical modules, optical chips, and optical network terminals, serving domestic and international customers. Over the past two decades, the company has leveraged its ability to produce and deliver a variety of high-quality products to empower global cloud service providers, telecom and network equipment suppliers, and operators, covering AI, cloud computing, FTTx, transmission networks, and wireless applications.
According to Frost & Sullivan, in 2025, based on global optical module revenue, the company held a 4.0% market share, ranking fifth among all professional optical module manufacturers globally; based on China optical module revenue, the company held a 10.1% market share, ranking third among all professional optical module manufacturers globally.
Related Articles

From "the purity of makeup removal" to "the sculpting of contours": Zhuben's "Four Seasons Fragrance Journey" 10th Anniversary Brand Gala Held in Hangzhou

CF PHARMTECH (02652) Global First-in-Class Inhaled New Drug ICF004 Successfully Completes First Healthy Volunteer Dosing in Phase I Clinical Trial, Industry-University-Research Collaborative Innovation Accelerates Breakthrough in Domestic Original Research

AI-developed new HIV drug, PCC nominated in 7 months! XtalPi (02228) incubated company Aiwei Tai achieves MPER structural breakthrough
From "the purity of makeup removal" to "the sculpting of contours": Zhuben's "Four Seasons Fragrance Journey" 10th Anniversary Brand Gala Held in Hangzhou

CF PHARMTECH (02652) Global First-in-Class Inhaled New Drug ICF004 Successfully Completes First Healthy Volunteer Dosing in Phase I Clinical Trial, Industry-University-Research Collaborative Innovation Accelerates Breakthrough in Domestic Original Research

AI-developed new HIV drug, PCC nominated in 7 months! XtalPi (02228) incubated company Aiwei Tai achieves MPER structural breakthrough

RECOMMEND





